FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564701342> ?p ?o ?g. }

• W2564701342 endingPage "2222" @default.
• W2564701342 startingPage "2222" @default.
• W2564701342 abstract "Abstract Abstract 2222 Hemophilia B is a congenital X-linked bleeding disorder whose severity is associated with diminished or absent levels of circulating FIX. Treatment with regular prophylactic FIX infusions has significant medical and quality of life benefits by maintaining adequate plasma levels of FIX for hemostasis approximating a non-diseased state. BAX326 nonacog gamma is a novel recombinant FIX (rFIX) that is manufactured without the addition of any materials of human or animal origin, and viral inactivation/reduction is achieved through solvent/detergent (S/D) treatment as well as 15nm nanofiltration. Pharmacokinetics, hemostatic efficacy and safety of BAX326 were assessed in a prospective clinical trial in patients aged 12 to 65 years with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B, previously treated with plasma-derived and/or recombinant FIX concentrates. PK parameters were compared with a commercially-available rFIX used as an active control in a crossover design. Hemostatic efficacy of BAX326 administered twice weekly as prophylaxis was compared with a historical control group treated on-demand. A total of 86 patients were enrolled and 73 were treated with BAX326. All subjects treated had previous exposure to a FIX concentrate for ≥ 150 days prior to entry into the study. Subjects included in the PK analysis (n=28) received one 75 ± 5 IU/kg infusion with BAX326 and one infusion with commercial rFIX in random order prior to receiving prophylactic treatment at a dose range from 40 to 60 IU/kg two times a week with BAX326. An additional 31 subjects also received prophylactic treatment (21–67 exposure days), and 14 subjects received BAX326 on-demand (5–25 exposure days). More than 70% of subjects had 50 or more exposure days to BAX326 during the study. PK equivalence between BAX326 and the comparator rFIX was confirmed as the 90% confidence intervals of the ratio (BAX326/comparator rFIX) of the geometric mean of AUC 0–72 h/dose (1.063 [1.03; 1.09]) was fully contained in the margins for equivalence (0.8 to 1.25). The mean half-life (T1/2) of BAX326 was 26.70h ± 9.55, and incremental recovery (IR) was 0.87 ± 0.22 IU/dL: IU/kg. Repeated PK analysis after 6 months of prophylactic treatment confirmed the results of the initial values. Twice weekly prophylactic treatment with BAX326 was effective in preventing bleeding episodes, with a significantly lower (79%, p<0.001) annualized bleed rate (ABR) during prophylaxis (mean ABR 4.20) compared to an on-demand treatment in a historical control group (mean ABR 20.0). Among the 56 subjects on prophylaxis, 24 subjects (43%) did not bleed; the mean ABR for joint bleeds was 2.79, and 1.70 for spontaneous bleeds. Of 238 total acute bleeds, 201 (84.4%) were controlled with 1–2 infusions of BAX326. Hemostatic efficacy at resolution of bleed was rated excellent or good in 95.4% of all treated bleeding episodes. The efficacy as related to degree of severity of bleeding episodes was excellent or good in 96.8 % of minor bleeds, 95 % of moderate bleeds and 92.9 % of major bleeding episodes. BAX326 was safe and well-tolerated, with similar adverse reaction rates to the comparator rFIX. The safety assessments demonstrate the safety and tolerability of BAX326 in patients with moderately severe or severe hemophilia B. There were no product related SAEs, no inhibitory or binding FIX antibodies, no antibodies to CHO, and no allergic reactions or thrombotic events; AEs considered related to BAX326 (dysgeusia and pain in extremity) were transient and mild, and occurred with an overall incidence of 2.7%. There were no treatment-related AEs within 24 hours after infusion. Elevated pre- and post-infusion values for thrombogenic markers (TAT, F1.2 and D-dimer) in some subjects did not reveal any pattern indicative of clinically relevant thrombogenicity with either BAX326 or the comparator rFIX, and were not associated with AEs. These data indicate that BAX326 is safe and efficacious in treating bleeding episodes and in routine prophylaxis in patients aged 12 years and older with hemophilia B. None of the historical risk factors, such as hypersensitivity reactions, inhibitor formation or thrombotic events were observed and few related adverse events occurred. Disclosures: Windyga: Baxter: Research Funding. Lissitchkov:Baxter: Research Funding. Stasyshyn:Baxter: Research Funding. Mamonov:Baxter: Research Funding. Rusen:Baxter: Research Funding. Lamas:Baxter: Research Funding. Oh:Baxter: Employment. Chapman:Baxter: Employment. Fritsch:Baxter: Employment. Pavlova:Baxter: Employment. Wong:Baxter: Employment. Abbuehl:Baxter: Employment." @default.
• W2564701342 created "2017-01-06" @default.
• W2564701342 creator A5010852837 @default.
• W2564701342 creator A5016306582 @default.
• W2564701342 creator A5022050468 @default.
• W2564701342 creator A5033329526 @default.
• W2564701342 creator A5037393708 @default.
• W2564701342 creator A5042493802 @default.
• W2564701342 creator A5042893306 @default.
• W2564701342 creator A5054363370 @default.
• W2564701342 creator A5064943069 @default.
• W2564701342 creator A5070415689 @default.
• W2564701342 creator A5071600573 @default.
• W2564701342 creator A5083717158 @default.
• W2564701342 date "2012-11-16" @default.
• W2564701342 modified "2023-09-28" @default.
• W2564701342 title "Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B." @default.
• W2564701342 doi "https://doi.org/10.1182/blood.v120.21.2222.2222" @default.
• W2564701342 hasPublicationYear "2012" @default.
• W2564701342 type Work @default.
• W2564701342 sameAs 2564701342 @default.
• W2564701342 citedByCount "1" @default.
• W2564701342 countsByYear W25647013422021 @default.
• W2564701342 crossrefType "journal-article" @default.
• W2564701342 hasAuthorship W2564701342A5010852837 @default.
• W2564701342 hasAuthorship W2564701342A5016306582 @default.
• W2564701342 hasAuthorship W2564701342A5022050468 @default.
• W2564701342 hasAuthorship W2564701342A5033329526 @default.
• W2564701342 hasAuthorship W2564701342A5037393708 @default.
• W2564701342 hasAuthorship W2564701342A5042493802 @default.
• W2564701342 hasAuthorship W2564701342A5042893306 @default.
• W2564701342 hasAuthorship W2564701342A5054363370 @default.
• W2564701342 hasAuthorship W2564701342A5064943069 @default.
• W2564701342 hasAuthorship W2564701342A5070415689 @default.
• W2564701342 hasAuthorship W2564701342A5071600573 @default.
• W2564701342 hasAuthorship W2564701342A5083717158 @default.
• W2564701342 hasConcept C104317684 @default.
• W2564701342 hasConcept C112705442 @default.
• W2564701342 hasConcept C126322002 @default.
• W2564701342 hasConcept C141071460 @default.
• W2564701342 hasConcept C142724271 @default.
• W2564701342 hasConcept C185592680 @default.
• W2564701342 hasConcept C188816634 @default.
• W2564701342 hasConcept C204787440 @default.
• W2564701342 hasConcept C27081682 @default.
• W2564701342 hasConcept C2778589496 @default.
• W2564701342 hasConcept C2781221834 @default.
• W2564701342 hasConcept C40767141 @default.
• W2564701342 hasConcept C42219234 @default.
• W2564701342 hasConcept C535046627 @default.
• W2564701342 hasConcept C55493867 @default.
• W2564701342 hasConcept C71924100 @default.
• W2564701342 hasConcept C87813604 @default.
• W2564701342 hasConcept C90924648 @default.
• W2564701342 hasConceptScore W2564701342C104317684 @default.
• W2564701342 hasConceptScore W2564701342C112705442 @default.
• W2564701342 hasConceptScore W2564701342C126322002 @default.
• W2564701342 hasConceptScore W2564701342C141071460 @default.
• W2564701342 hasConceptScore W2564701342C142724271 @default.
• W2564701342 hasConceptScore W2564701342C185592680 @default.
• W2564701342 hasConceptScore W2564701342C188816634 @default.
• W2564701342 hasConceptScore W2564701342C204787440 @default.
• W2564701342 hasConceptScore W2564701342C27081682 @default.
• W2564701342 hasConceptScore W2564701342C2778589496 @default.
• W2564701342 hasConceptScore W2564701342C2781221834 @default.
• W2564701342 hasConceptScore W2564701342C40767141 @default.
• W2564701342 hasConceptScore W2564701342C42219234 @default.
• W2564701342 hasConceptScore W2564701342C535046627 @default.
• W2564701342 hasConceptScore W2564701342C55493867 @default.
• W2564701342 hasConceptScore W2564701342C71924100 @default.
• W2564701342 hasConceptScore W2564701342C87813604 @default.
• W2564701342 hasConceptScore W2564701342C90924648 @default.
• W2564701342 hasIssue "21" @default.
• W2564701342 hasLocation W25647013421 @default.
• W2564701342 hasOpenAccess W2564701342 @default.
• W2564701342 hasPrimaryLocation W25647013421 @default.
• W2564701342 hasRelatedWork W2048164325 @default.
• W2564701342 hasRelatedWork W2129428300 @default.
• W2564701342 hasRelatedWork W2304955612 @default.
• W2564701342 hasRelatedWork W2357768821 @default.
• W2564701342 hasRelatedWork W2365071841 @default.
• W2564701342 hasRelatedWork W2417138647 @default.
• W2564701342 hasRelatedWork W2564701342 @default.
• W2564701342 hasRelatedWork W2767252183 @default.
• W2564701342 hasRelatedWork W3132140644 @default.
• W2564701342 hasRelatedWork W4235734420 @default.
• W2564701342 hasVolume "120" @default.
• W2564701342 isParatext "false" @default.
• W2564701342 isRetracted "false" @default.
• W2564701342 magId "2564701342" @default.
• W2564701342 workType "article" @default.